The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo

Pharmacological Research

Volumn 56, Issue 4, 2007, Pages 335-343

  Li, Ying Yin ^a   Wu, Hao Shu ^a   Tang, Lei ^b   Feng, Chu Rui ^a   Yu, Juan Hong ^c   Li, Yu ^b   Yang, Yu She ^c   Yang, Bo ^a   He, Qiao Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Adipocytokines; Antidiabetes; GY3; Insulin sensitizing

Indexed keywords

1 (4 CHLOROBENZOYL) 5 HYDROXY 2 METHYL 3 INDOLEACETITIC ACID; ADIPONECTIN; DEXAMETHASONE; GLUCOSE; GLUCOSE TRANSPORTER 4; INDOLE DERIVATIVE; INSULIN; ISOBUTYLMETHYLXANTHINE; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; CELL DIFFERENTIATION; CELL LINE, TUMOR; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPOGLYCEMIC AGENTS; INDOLEACETIC ACIDS; INDOLES; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PPAR ALPHA; PPAR GAMMA; RESISTIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 34848816197     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.08.002     Document Type: Article

References (35)

1. Porte D.J., and Schwartz M.W. Diabetes complications: why is glucose potentially toxic?. Science 272 (1996) 699-700
2. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
3. Bhatia V., and Viswanathan P. Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs 7 (2006) 891-897
4. Boden G., Homko C., Mozzoli M., Showe L.C., Nichols C., and Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54 (2005) 880-885
5. Miyazaki Y., He H., Mandarino L.J., and DeFronzo R.A. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52 (2003) 1943-1950
6. Phillips S.A., Ciaraldi T.P., Kong A.P., Bandukwala R., Aroda V., Carter L., et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52 (2003) 667-674
7. Combs T.P., Wagner J.A., Berger J., Doebber T., Wang W.J., Zhang B.B., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 143 3 (2002) 998-1007
8. Vasudevan A.R., and Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 6 (2004) 850-863
9. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 103 (2006) 443-448
10. Ahima R.S. Adipose tissue as an endocrine organ. Obesity 14 5 (2006) 242S-249S
11. Ramirez-Zacarias J.L., Castro-Munozledo F., and Kuri-Harcuch W. Quantition of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 97 (1992) 493-497
12. Deng T., Shan S., Li Z.B., Wu Z.W., Liao C.Z., Ko B., et al. A new retinoid-like compound that activates perpxisome proliferator-activated receptors and lower blood glucose in diabetic mice. Biol Pharm Bull 28 7 (2005) 1192-1196
13. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 2 (2002) S10-S15
14. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101 (1998) 1354-1361
15. Cammisotto P.G., and Bukowiecki L.J. Mechanisms of leptin secretion from white adipocytes. Am J Physiol Cell Physiol 283 (2002) C244-C250
16. Hartman H.B., Hu X., Tyler K.X., Dalal C.K., and Lazar M.A. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 277 (2002) 19754-19761
17. Kitagawa K., Rosen B.S., Spiegelman B.M., Lienhard G.E., and Tanner L.I. Insulin stimulates the acute release of adipsin from 3T3-L1 adipocytes. Biochim Biophys Acta 1014 (1989) 83-89
18. Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. Curr Mol Med 5 (2005) 333-339
19. Shojima N., Sakoda H., Ogihara T., Fujishiro M., Katagiri H., Anai M., et al. Humoral regulation of resistin expression in 3T3-L1 adipocytes and mouse adipose cells. Diabetes 51 (2002) 1737-1744
20. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
21. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 580 (2006) 2917-2921
22. Trujillo M.E., and Scherer P.E. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
23. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J Biol Chem 281 (2006) 2654-2660
24. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
25. Webber J. Energy balance in obesity. Proc Nutr Soc 62 (2003) 539-543
26. Haque Z., and Rahman M.A. Serum leptin levels in female patients with NIDDM. J Coll Physicians Surg Pak 13 3 (2003) 130-134
27. Marita A.R., Sarkar J.A., and Rane S. Type 2 diabetes in non-obese Indian subjects is associated with reduced leptin levels: study from Mumbai, Western India. Mol Cell Biochem 275 (2005) 143-151
28. Ukkola O. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander?. Eur J Endocrinol 147 (2002) 571-574
29. Shuldiner A.R., Yang R., and Gong D.-W. Resistin, obesity, and insulin resistance-the emerging role of the adipocyte as an endocrine organ. N Engl J Med 345 (2001) 1345-1346
30. Way J.M., Görgün C.Z., Tong Q., Uysal K.T., Brown K.K., Harrington W.W., et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276 (2001) 25651-25653
31. Le Lay S.L., Boucher J., Rey A., Castan-Laurell I., Krief S., Ferre P., et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 289 (2001) 564-567
32. Moore G.B., Chapman H., Holder J.C., Lister C.A., Piercy V., Smith S.A., et al. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 286 (2001) 735-741
33. Haluzik M.M., Lacinova Z., Dolinkova M., Haluzikova D., Housa D., Horinek A., et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 147 (2006) 4517-4524
34. Farese R.V., Sajan M.P., and Standaert M.L. Insulin-sensitivie protein kinase (atypical protein kinase C and protrein kinase B/Akt): actions and defects in obesity and type 2 diabetes. Exp Biol Med 230 (2005) 593-605
35. Bloomgarden Z.T. Thiazolidinediones. Diabetes Care 28 (2005) 488-493